Skip to main content
BioCentury on BioBusiness
Feature Story

Cover Story: Strategy: Momenta moving on

Why Momenta abandoning complex generics in favor of novel drugs and biosimilars

By Catherine Shaffer, Senior Writer

Data announced in October represent the first fruits of Momenta Pharmaceuticals Inc.'s novel drug pipeline, which will play a larger role in the company's strategy going forward as it steps back from complex generics.

Momenta was founded in 2001 to develop a platform technology to analyze complex carbohydrate molecules that are beyond the reach of conventional methods of characterization. By using the technology to solve what had been scientifically intractable problems, the company hoped to build a portfolio of complex generics, novel drugs and biosimilars — all of which would be insulated from competition by either IP or know-how created by the platform.

Full Article

Today's Biotech & Pharma News



    Universal reversal for heparin

    A synthetic, universal heparin reversal agent could provide a lower-risk option for preventing bleeding during surgery than protamine, the standard of care, but finding industry partners could be the challenge.


    Terazosin reborn

    Chinese researchers have found that the generic alpha-blocker terazosin prevents apoptosis and want to pursue it for stroke, but they will need to navigate a landscape of difficult preclinical models.

  • PIEZO de resistance

    A Duke team has found a new role for PIEZO calcium channels in cartilage damage, suggesting channel inhibitors could be developed for joint injury or osteoarthritis.

  • Lysin in wait

    Micreos and ContraFect are separately developing phage lysins, which are not prone to bacterial resistance, as complements to antibiotics.


    This Week in Therapeutics

    miR-24 to prevent abdominal aortic aneurysms; demethyleneberberine to treat alcoholic liver disease; distal airway stem cell transplants to regenerate injured lung tissue; and more...


    This Week in Techniques

    Controlling Plasmodium falciparum gene expression to identify new malaria targets; using gp130-expressing mice as models of MM; diagnosing familial cold autoinflammatory syndrome with an NLRC4 mutation; and more...

Subscribe Now
Free Trial